India · Delayed Price · Currency is INR Marinus Pharmaceuticals Statistics
Total Valuation
Concord Biotech has a market cap or net worth of INR 167.18 billion. The enterprise value is 164.03 billion.
| Market Cap | 167.18B |
| Enterprise Value | 164.03B |
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 104.62M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 26.20M |
Valuation Ratios
The trailing PE ratio is 46.95 and the forward PE ratio is 34.68.
| PE Ratio | 46.95 |
| Forward PE | 34.68 |
| PS Ratio | 14.03 |
| PB Ratio | 9.22 |
| P/TBV Ratio | 9.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 46.06 |
| EV / Sales | 13.76 |
| EV / EBITDA | 33.84 |
| EV / EBIT | 38.18 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | n/a |
| Interest Coverage | 1,241.28 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 16.07% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 8.65M |
| Profits Per Employee | 2.59M |
| Employee Count | 1,377 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Concord Biotech has paid 1.18 billion in taxes.
| Income Tax | 1.18B |
| Effective Tax Rate | 24.83% |
Stock Price Statistics
The stock price has increased by +3.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +3.89% |
| 50-Day Moving Average | 1,856.87 |
| 200-Day Moving Average | 1,863.52 |
| Relative Strength Index (RSI) | 26.51 |
| Average Volume (20 Days) | 6,301 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Concord Biotech had revenue of INR 11.92 billion and earned 3.56 billion in profits. Earnings per share was 34.03.
| Revenue | 11.92B |
| Gross Profit | 7.75B |
| Operating Income | 4.31B |
| Pretax Income | 4.74B |
| Net Income | 3.56B |
| EBITDA | 4.86B |
| EBIT | 4.31B |
| Earnings Per Share (EPS) | 34.03 |
Balance Sheet
The company has 3.18 billion in cash and 29.69 million in debt, giving a net cash position of 3.15 billion.
| Cash & Cash Equivalents | 3.18B |
| Total Debt | 29.69M |
| Net Cash | 3.15B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 18.13B |
| Book Value Per Share | 173.25 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 65.02%, with operating and profit margins of 36.16% and 29.88%.
| Gross Margin | 65.02% |
| Operating Margin | 36.16% |
| Pretax Margin | 39.76% |
| Profit Margin | 29.88% |
| EBITDA Margin | 40.77% |
| EBIT Margin | 36.16% |
| FCF Margin | n/a |
Dividends & Yields
Concord Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.05% |
| Shareholder Yield | n/a |
| Earnings Yield | 2.13% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |